Ardelyx Inc (NAS:ARDX)
$ 5.67 -0.02 (-0.35%) Market Cap: 1.34 Bil Enterprise Value: 1.26 Bil PE Ratio: 0 PB Ratio: 8.49 GF Score: 75/100

Ardelyx Inc Update Call Transcript

Dec 29, 2022 / 01:00PM GMT
Release Date Price: $2.53 (+0.80%)
Operator

Good morning, and welcome to Ardelyx's conference call. (Operator Instructions) As a reminder, today's call is being recorded. I would now like to turn the call over to Caitlin Lowie, Vice President, Corporate Communications and Investor Relations. You may begin.

Caitlin Lowie

Thank you, and good morning, everyone. This morning, we issued a press release announcing the FDA Office of New Drugs' decision regarding the New Drug Application, or NDA for XPHOZAH from the Cardiovascular and Renal Drugs Advisory Committee meeting convened on November 16, 2022.

During this call, we will refer to today's press release which is available on the Investors section of the company's website at ardelyx.com. On the call with me today with prepared remarks are Mike Raab, President and CEO; and Susan Rodriguez, Chief Commercial Officer. Dr. Laura Williams, Chief Medical Officer; Justin Renz, Chief Financial Officer; and Rob Blanks, Chief Regulatory Affairs and Quality Assurance Officer will join us for the question-and-answer period.

During this call, we will be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot